BCAB News and Press, BioAtla Inc. From 06/26/23

SAN DIEGO, June 26, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company has been added as a ...

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...

2023-05-12 10:03:10 ET Gainers: ARS Pharmaceuticals ( SPRY ) +77% . Dermata Therapeutics ( DRMA ) +63% . AirSculpt Technologies ( AIRS ) +27% . GlycoMimetics ( GLYC ) +14% . BioAtla ( BCAB ) +13% . Losers: Heron Thera...

2023-05-11 22:51:02 ET BioAtla, Inc. (BCAB) Q1 2023 Earnings Conference Call May 11, 2023 04:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman and CEO Richard Waldron - CFO Philippe Martin - Chief CDO Conference...

Advancing CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS); expect Leiomyosarcoma (LMS) cohort readout in 2H23 On track for submitting a meeting request to the Food & Drug Administration (FDA...

SAN DIEGO, May 08, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management w...

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference cal...

2023-03-23 22:33:04 ET BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief F...

- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS) cohort readout in 2H23 - Initiated the potentially registrational Phase 2, part 2 BA3011 Undifferentiated Pleomorphic Sarcoma (UPS) st...

SAN DIEGO, March 16, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference c...